Shopping Cart 0
Cart Subtotal
USD 0

Antihypertensive Drugs Market by Therapeutic Class (Diuretics, ACE Inhibitors, Calcium Channel Blockers, Vasodilators, Beta-adrenergic Blockers, and Others) and Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-commerce, and Others Distribution Channel): Global Opportunity Analysis and Industry Forecast, 2019-2026

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 5370

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 8995

Details

The global antihypertensive market accounted for USD 22,557 million in 2018, and is expected to reach USD 28,797 million by 2026, registering a CAGR of 3.1% from 2019 to 2026.
Antihypertensive drugs are employed for the treatment of patients suffering from hypertension. Hypertension is a medical condition, which involves rise in blood pressure in the arteries. Furthermore, the patient suffering from hypertension is highly susceptible to other complications, which include heart failure and aneurysm. Therefore, the treatment of this medical condition requires early diagnosis and management by the use of antihypertensive drugs. Some of the antihypertensive drugs available in the market include beta blockers, calcium channel blockers, and vasodilators. These drugs are prescribed by a physician, and are available in retail stores and hospital pharmacies.
The growth of the global antihypertensive market is driven by surge in incidence of hypertension across the globe. Furthermore, rise in awareness related to complications associated with hypertension is another major factor that fuels the growth of the market. Moreover, increase in geriatric population and sedentary lifestyle act as key drivers of the global market. However, recent patent expirations hinder the growth of the antihypertensive market. Conversely, surge in research related to antihypertensive drugs in emerging economies is expected to offer lucrative opportunities during the forecast period.
The global antihypertensive market size is segmented into therapeutic class, distribution channel, and region. On the basis of therapeutic class, the market is fragmented into diuretics, ACE inhibitors, calcium channel blockers, vasodilators, beta-adrenergic blockers, and others. Depending on distribution channel, it is segregated into retail pharmacy, hospital pharmacy, and e-commerce. Region wise, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
This report entails a detailed quantitative analysis along with the current global antihypertensive market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
The market size and estimations are based on a comprehensive analysis of key developments in the industry.
A qualitative analysis based on innovative products facilitates strategic business planning.
The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments
By Therapeutic Class
o Diuretics
o ACE Inhibitors
o Calcium Channel Blockers
o Beta-adrenergic Blockers
o Vasodilators
o Others
By Distribution Channel
o Retail Pharmacy
o Hospital Pharmacy
o E-commerce
By Region
o North America
U.S.
Canada
Mexico
o Europe
Germany
France
UK
Italy
Spain
Rest of Europe
o Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
o LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
List of key players profiled in the report
Boehringer Ingelheim GmbH
Merck KGaA
Johnson and Johnson
Bayer AG
Pfizer, Inc.
Takeda Pharmaceutical Co., Ltd.
AstraZeneca plc
Daiichi Sankyo Company
Sanofi S.A.
Novartis International AG
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
Merck
United Therapeutics Corporation Safe In Breastfeeding
 
READ MORE

Table Of Content

Scope

Chapter 1: Introduction

 

1.1. Report Description

1.2. Key Market Segments

 

1.2.1. List of Key Players Profiled In The Report

 

1.3. Research Methodology

 

1.3.1. Primary Research

1.3.2. Secondary Research

1.3.3. Analyst Tools And Models

 

Chapter 2: Executive Summary

 

2.1. Key Findings of The Study

2.2. Cxo Perspective

 

Chapter 3: Market Overview

 

3.1. Market Definition And Scope

3.2. Top Player Positioning

 

3.2.1. Top Investment Pockets

 

3.3. Key Forces Shaping Antihypertensive Industry/Market

3.4. Market Dynamics

 

3.4.1. Drivers

 

3.4.1.1. Surge In Geriatric Population Worldwide

3.4.1.2. Surge In Healthcare Expenditure Worldwide

3.4.1.3. Rise In Prevalence of Hypertension Across The Globe

 

3.4.2. Restraint

 

3.4.2.1. Patent Expirations of Blockbuster Drugs

 

3.4.3. Opportunity

 

3.4.3.1. High Growth Potential In Developing Economies

 

3.4.4. Impact Analyses

 

Chapter 4: Antihypertensive Drugs Market, By Drug Class

 

4.1. Overview

 

4.1.1. Market Size And Forecast

 

4.2. Diuretics

 

4.2.1. Key Market Trends, Growth Factors, And Opportunities

4.2.2. Market Size And Forecast, By Region

4.2.3. Market Analysis By Country

 

4.3. Ace Inhibitors

 

4.3.1. Key Market Trends, Growth Factors, And Opportunities

4.3.2. Market Size And Forecast, By Region

4.3.3. Market Analysis By Country

 

4.4. Calcium Channel Blockers

 

4.4.1. Key Market Trends, Growth Factors, And Opportunities

4.4.2. Market Size And Forecast, By Region

4.4.3. Market Analysis By Country

 

4.5. Beta-Adrenergic Blockers

 

4.5.1. Key Market Trends, Growth Factors, And Opportunities

4.5.2. Market Size And Forecast, By Region

4.5.3. Market Analysis By Country

 

4.6. Vasodilators

 

4.6.1. Key Market Trends, Growth Factors, And Opportunities

4.6.2. Market Size And Forecast, By Region

4.6.3. Market Analysis By Country

 

4.7. Others

 

4.7.1. Key Market Trends, Growth Factors, And Opportunities

4.7.2. Market Size And Forecast, By Region

4.7.3. Market Analysis By Country

 

Chapter 5: Antihypertensive Drugs Market, By End User

 

5.1. Overview

 

5.1.1. Market Size And Forecast

 

5.2. Retail Pharmacy

 

5.2.1. Market Size And Forecast, By Region

5.2.2. Market Analysis By Country

 

5.3. Hospital Pharmacy

 

5.3.1. Market Size And Forecast, By Region

5.3.2. Market Analysis By Country

 

5.4. E-Commerce Websites & Online Drug Stores

 

5.4.1. Market Size And Forecast, By Region

5.4.2. Market Analysis By Country

 

Chapter 6: Antihypertensive Drugs Market, By Region

 

6.1. Overview

 

6.1.1. Market Size And Forecast

 

6.2. North America

 

6.2.1. Key Market Trends And Opportunities

6.2.2. Market Analysis, By Country

 

6.2.2.1. U.S.

 

6.2.2.1.1. U.S. Market Size And Forecast, By Drug Class

6.2.2.1.2. U.S. Market Size And Forecast, By Distribution Channel

 

6.2.2.2. Canada

 

6.2.2.2.1. Canada Market Size And Forecast, By Drug Class

6.2.2.2.2. Canada Market Size And Forecast, By Distribution Channel

 

6.2.2.3. Mexico

 

6.2.2.3.1. Mexico Market Size And Forecast, By Drug Class

6.2.2.3.2. Mexico Market Size And Forecast, By Distribution Channel

 

6.2.3. North America Market Size And Forecast, By Drug Class

6.2.4. North America Market Size And Forecast, By Distribution Channel

 

6.3. Europe

 

6.3.1. Key Market Trends And Opportunities

6.3.2. Market Analysis, By Country

 

6.3.2.1. Germany

 

6.3.2.1.1. Germany Market Size And Forecast, By Drug Class

6.3.2.1.2. Germany Market Size And Forecast, By Distribution Channel

 

6.3.2.2. France

 

6.3.2.2.1. France Market Size And Forecast, By Drug Class

6.3.2.2.2. France Market Size And Forecast, By Distribution Channel

 

6.3.2.3. Uk

 

6.3.2.3.1. Uk Market Size And Forecast, By Drug Class

6.3.2.3.2. Uk Market Size And Forecast, By Distribution Channel

 

6.3.2.4. Italy

 

6.3.2.4.1. Italy Market Size And Forecast, By Drug Class

6.3.2.4.2. Italy Market Size And Forecast, By Distribution Channel

 

6.3.2.5. Rest of Europe

 

6.3.2.5.1. Rest of Europe Market Size And Forecast, By Drug Class

6.3.2.5.2. Rest of Europe Market Size And Forecast, By Distribution Channel

 

6.3.3. Europe Market Size And Forecast, By Drug Class

6.3.4. Europe Market Size And Forecast, By Distribution Channel

 

6.4. Asia-Pacific

 

6.4.1. Key Market Trends And Opportunities

6.4.2. Market Analysis, By Country

 

6.4.2.1. Japan

 

6.4.2.1.1. Japan Market Size And Forecast, By Drug Class

6.4.2.1.2. Japan Market Size And Forecast, By Distribution Channel

 

6.4.2.2. China

 

6.4.2.2.1. China Market Size And Forecast, By Drug Class

6.4.2.2.2. China Market Size And Forecast, By Distribution Channel

 

6.4.2.3. India

 

6.4.2.3.1. India Market Size And Forecast, By Drug Class

6.4.2.3.2. India Market Size And Forecast, By Distribution Channel

 

6.4.2.4. Rest of Asia-Pacific

 

6.4.2.4.1. Rest of Asia-Pacific Market Size And Forecast, By Drug Class

6.4.2.4.2. Rest of Asia-Pacific Market Size And Forecast, By Distribution Channel

 

6.4.3. Asia-Pacific Market Size And Forecast, By Drug Class

6.4.4. Asia-Pacific Market Size And Forecast, By Distribution Channel

 

6.5. Lamea

 

6.5.1. Key Market Trends And Opportunities

6.5.2. Market Analysis, By Country

 

6.5.2.1. Brazil

 

6.5.2.1.1. Brazil Market Size And Forecast, By Drug Class

6.5.2.1.2. Brazil Market Size And Forecast, By Distribution Channel

 

6.5.2.2. South Africa

 

6.5.2.2.1. South Africa Market Size And Forecast, By Drug Class

6.5.2.2.2. South Africa Market Size And Forecast, By Distribution Channel

 

6.5.2.3. Saudi Arabia

 

6.5.2.3.1. Saudi Arabia Market Size And Forecast, By Drug Class

6.5.2.3.2. Saudi Arabia Market Size And Forecast, By Distribution Channel

 

6.5.2.4. Rest of Lamea

 

6.5.2.4.1. Rest of Lamea Market Size And Forecast, By Drug Class

6.5.2.4.2. Rest of Lamea Market Size And Forecast, By Distribution Channel

 

6.5.3. Lamea Market Size And Forecast, By Drug Class

6.5.4. Lamea Market Size And Forecast, By Distribution Channel

 

Chapter 7: Company Profiles

 

7.1. Astrazeneca Plc

 

7.1.1. Company Overview

7.1.2. Company Snapshot

7.1.3. Operating Business Segments

7.1.4. Product Portfolio

7.1.5. Business Performance

 

7.2. Boehringer Ingelheim International Gmbh

 

7.2.1. Company Overview

7.2.2. Company Snapshot

7.2.3. Operating Business Segments

7.2.4. Product Portfolio

7.2.5. Business Performance

 

7.3. Daiichi Sankyo Company, Limited

 

7.3.1. Company Overview

7.3.2. Operating Business Segments

7.3.3. Product Portfolio

7.3.4. Business Performance

7.3.5. Key Strategic Moves And Developments

 

7.4. Johnson & Johnson

 

7.4.1. Company Overview

7.4.2. Company Snapshot

7.4.3. Operating Business Segments

7.4.4. Product Portfolio

7.4.5. Business Performance

 

7.5. Lupin

 

7.5.1. Company Overview

7.5.2. Company Snapshot

7.5.3. Operating Business Segments

7.5.4. Product Portfolio

7.5.5. Business Performance

 

7.6. Novartis Ag.

 

7.6.1. Company Overview

7.6.2. Company Snapshot

7.6.3. Operating Business Segments

7.6.4. Product Portfolio

7.6.5. Business Performance

 

7.7. Merck & Co., Inc

 

7.7.1. Company Overview

7.7.2. Company Snapshot

7.7.3. Operating Business Segments

7.7.4. Product Portfolio

7.7.5. Business Performance

 

7.8. Pfizer Inc.

 

7.8.1. Company Overview

7.8.2. Company Snapshot

7.8.3. Operating Business Segments

7.8.4. Product Portfolio

7.8.5. Business Performance

 

7.9. Sun Pharmaceutical Industries Ltd. (Ranbaxy Laboratories)

 

7.9.1. Company Overview

7.9.2. Company Snapshot

7.9.3. Operating Business Segments

7.9.4. Product Portfolio

7.9.5. Business Performance

7.9.6. Key Strategic Moves And Developments

 

7.10. Sanofi

 

7.10.1. Company Overview

7.10.2. Operating Business Segments

7.10.3. Product Portfolio

7.10.4. Business Performance


List Of Figure

List of Figures

 

Figure 01. Global Antihypertensive Drugs Market Segmentation

Figure 02. Top Player Positioning, 2018

Figure 03. Top Investment Pockets

Figure 04. Moderate Bargaining Power of Supplier

Figure 05. Low Bargaining Power of Buyers

Figure 06. Low Threat of Substitutes

Figure 07. High Intensity of Rivalry

Figure 08. Low Threat of New Entrant

Figure 09. World Population Aged 65 And Over (%)

Figure 10. Impact Analyses, Antihypertensive Drugs Market

Figure 11. Comparative Share Analysis of Diuretics Market, By Country, 2018 & 2026 (%)

Figure 12. Comparative Share Analysis of Ace Inhibitors Antihypertensive Drugs Market, By Country, 2018 & 2026 (%)

Figure 13. Comparative Share Analysis of Calcium Channel Blockers Antihypertensive Drugs Market, By Country, 2018 & 2026 (%)

Figure 14. Comparative Share Analysis of Beta-Adrenergic Blockers Antihypertensive Drugs Market, By Country, 2018 & 2026 (%)

Figure 15. Comparative Share Analysis of Vasodilators Antihypertensive Drugs Market, By Country, 2018 & 2026 (%)

Figure 16. Comparative Share Analysis of Others Antihypertensive Drugs Market, By Country, 2018 & 2026 (%)

Figure 17. Comparative Share Analysis of Antihypertensive Drugs Market For Retail Pharmacy, By Country, 2018 & 2026 (%)

Figure 18. Comparative Share Analysis of Antihypertensive Drugs Market For Hospital Pharmacy, By Country, 2018 & 2026 (%)

Figure 19. Comparative Share Analysis of Antihypertensive Drugs Market For E-Commerce Websites & Online Drug Stores, By Country, 2018 & 2026 (%)

Figure 20. U.S. Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 21. Canada Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 22. Mexico Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 23. Comparison of Male Geriatric Population In European Countries, 2017 (Million)

Figure 24. Germany Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 25. France Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 26. Uk Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 27. Italy Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 28. Rest of Europe Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 29. Japan Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 30. China Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 31. India Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 32. Rest of Asia-Pacific Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 33. Brazil Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 34. South Africa Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 35. Saudi Arabia Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 36. Rest of Lamea Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 37. Astrazeneca: Net Sales, 2016-2018 (USD Million)

Figure 38. Astrazeneca: Revenue Share By Region, 2018(%)

Figure 39. Boehringer Ingelheim: Net Sales, 2016-2018 (USD Million)

Figure 40. Boehringer Ingelheim: Revenue Share By Segment, 2018 (%)

Figure 41. Boehringer Ingelheim: Revenue Share By Region, 2018(%)

Figure 42. Daiichi-Sankyo: Net Sales, 2016-2018 (USD Million)

Figure 43. Daiichi-Sankyo: Revenue Share By Segment, 2018 (%)

Figure 44. Daiichi-Sankyo: Revenue Share By Region, 2018(%)

Figure 45. J&J: Net Sales, 2016-2018 (USD Million)

Figure 46. J&J: Revenue Share By Segment, 2018 (%)

Figure 47. J&J: Revenue Share By Region, 2018(%)

Figure 48. Lupin: Net Sales, 2017-2019 (USD Million)

Figure 49. Lupin: Revenue Share By Region, 2019(%)

Figure 50. Novartis Ag: Net Sales, 2016-2018 (USD Million)

Figure 51. Novartis Ag: Revenue Share By Segment, 2018 (%)

Figure 52. Novartis Ag: Revenue Share By Geography, 2018 (%)

Figure 53. Merck: Net Sales, 2016-2018 (USD Million)

Figure 54. Merck: Revenue Share By Segment, 2018 (%)

Figure 55. Merck: Revenue Share By Region, 2018(%)

Figure 56. Pfizer: Net Sales, 2016-2018 (USD Million)

Figure 57. Pfizer: Revenue Share By Segment, 2018 (%)

Figure 58. Pfizer: Revenue Share By Region, 2018(%)

Figure 59. Sun Pharma: Net Sales, 2016-2018 (USD Million)

Figure 60. Sun Pharma: Revenue Share By Region, 2018(%)

Figure 61. Sanofi: Net Sales, 2016-2018 (USD Million)

Figure 62. Sanofi: Revenue Share By Segment, 2018 (%)

Figure 63. Sanofi: Revenue Share By Region, 2018(%)


List Of Table

List of Tables

 

Table 01. Global Antihypertensive Drugs Market, By Drug Class, 2018-2026 (USD Million)

Table 02. Diuretics Antihypertensive Drugs Market, By Region, 2018-2026 (USD Million)

Table 03. Ace Inhibitors Antihypertensive Drugs Market, By Region, 2018-2026 (USD Million)

Table 04. Calcium Channel Blockers Antihypertensive Drugs Market, By Region, 2018-2026 (USD Million)

Table 05. Beta-Adrenergic Blockers Antihypertensive Drugs Market, By Region, 2018-2026 (USD Million)

Table 06. Vasodilators Antihypertensive Drugs Market, By Region, 2018-2026 (USD Million)

Table 07. Others Antihypertensive Drugs Market, By Region, 2018-2026 (USD Million)

Table 08. Global Antihypertensive Drugs Market, By Distribution Channel, 2018-2026 (USD Million )

Table 09. Antihypertensive Drugs Market Revenue For Retail Pharmacy, By Region 2018-2026(USD Million)

Table 10. Antihypertensive Drugs Market Revenue For Hospital Pharmacy, By Region 2018-2026 (USD Million)

Table 11. Antihypertensive Drugs Market Revenue For E-Commerce Websites & Online Drug Stores, By Region 2018-2026 (USD Million)

Table 12. Antihypertensive Drugs Market, By Region, 2018-2026 (USD Million)

Table 13. North America Antihypertensive Drugs Market Revenue, By Country, 2019-2026 (USD Million)

Table 14. U.S. Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 15. U.S. Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 16. Canada Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 17. Canada Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 18. Mexico Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 19. Mexico Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 20. North America Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026(USD Million)

Table 21. North America Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026(USD Million)

Table 22. Europe Antihypertensive Drugs Market Revenue, By Country, 2019-2026 (USD Million)

Table 23. Germany Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 24. Germany Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 25. France Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 26. France Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 27. Uk Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 28. Uk Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 29. Italy Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 30. Italy Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 31. Rest of Europe Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 32. Rest of Europe Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 33. Europe Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026(USD Million)

Table 34. Europe Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026(USD Million)

Table 35. Asia-Pacific Antihypertensive Drugs Market Revenue, By Country, 2019-2026 (USD Million)

Table 36. Japan Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 37. Japan Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 38. China Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 39. China Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 40. India Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 41. India Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 42. Rest of Asia-Pacific Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 43. Rest of Asia-Pacific Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 44. Asia-Pacific Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026(USD Million)

Table 45. Asia-Pacific Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026(USD Million)

Table 46. Lamea Antihypertensive Drugs Market Revenue, By Country, 2019-2026 (USD Million)

Table 47. Brazil Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 48. Brazil Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 49. South Africa Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 50. South Africa Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 51. Saudi Arabia Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 52. Saudi Arabia Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 53. Rest of Lamea Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 54. Rest of Lamea Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 55. Lamea Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026(USD Million)

Table 56. Lamea Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026(USD Million)

Table 57. Astrazeneca: Company Snapshot

Table 58. Astrazeneca: Operating Business Segments

Table 59. Astrazeneca: Product Portfolio

Table 60. Boehringer Ingelheim: Company Snapshot

Table 61. Boehringer Ingelheim: Product Business Segments

Table 62. Boehringer Ingelheim: Product Portfolio

Table 63. Daiichi-Sankyo.: Company Snapshot

Table 64. Daiichi-Sankyo.: Operating Business Segments

Table 65. Daiichi-Sankyo.: Product Portfolio

Table 66. J&J: Company Snapshot

Table 67. J&J: Operating Business Segments

Table 68. J&J: Product Portfolio

Table 69. Lupin: Company Snapshot

Table 70. Lupin: Operating Segments

Table 71. Lupin: Product Portfolio

Table 72. Novartis: Company Snapshot

Table 73. Novartis: Operating Business Segments

Table 74. Novartis: Product Portfolio

Table 75. Merck: Company Snapshot

Table 76. Merck: Operating Segments

Table 77. Merck: Product Portfolio

Table 78. Pfizer: Company Snapshot

Table 79. Pfizer: Operating Segments

Table 80. Pfizer: Product Portfolio

Table 81. Sun Pharma: Company Snapshot

Table 82. Sun Pharma: Product Portfolio

Table 83. Sanofi: Company Snapshot

Table 84. Sanofi: Product Portfolio

Licence Rights

Single-User license:

This  grants one non-exclusive, non-transferable machine-readable license for the report either electronically or online. The right to store, display, use, or stockpile the report is restricted to only ONE authorized computer. For obtaining a single user license, ONLY an individual ("you") for individual use is entitled for using the product or as mentioned in the License Terms. Any individual representing an organization is refrained from accessing the products/services of AMR or as stated in the License Terms; any breach of which shall lead to violation of applicable laws in the United States, India, or in the jurisdiction of purchase. The products and services offered are the intellectual property of AMR, and are protected by applicable copyright laws, international treaty provisions, and other applicable laws of the country in which these are being used. Albeit the abovementioned, you are NOT be permitted to:

transmit or permit any third party to use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to assign the rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial/noncommercial gains

share the information or content either electronically or in printed form with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization or any other unauthorized users.

 

Five-User License:

This  grants up to Five non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online. The right to store, transfer, display, use, or stockpile the report is restricted to only FIVE authorized users. An individual representing an organization or an organization shall ONLY purchase the five-user license. The authorized users can print additional duplicate printed copies of the report for distribution to the employees of his/her company (Personnel). Albeit the abovementioned, you are NOT be permitted to:

 

transmit or permit by any means to any third party (i.e. non-personnel) or unauthorized users for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to redistribute or assign rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; exclusively permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial or noncommercial gains.

share the information or content either electronically or as printed copies with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization, or to more than 5 AUTHORIZED USERS.

 

Enterprise License:

This  grants global, non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online, within the organization and/or its subsidiaries. The authorized users shall have complete right to store, display, transfer, and/or use the report ONLY within the organization or its subsidiaries. Authorized users can take unlimited printed copies of the report for distribution among its employees. Albeit the abovementioned, you shall NOT be permitted to:

transmit or permit by any means to any third party (i.e. non-personnel) for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer or attempt to assign the rights in the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Boehringer Ingelheim GmbH, Merck KGaA, Johnson and Johnson, Bayer AG, Pfizer, Inc. Takeda Pharmaceutical Co., Ltd., AstraZeneca plc, Daiichi Sankyo Company, Sanofi S.A., and Novartis International AG.

Company Profile

Company Profile Title

The global antihypertensive market accounted for USD 22,557 million in 2018, and is expected to reach USD 28,797 million by 2026, registering a CAGR of 3.1% from 2019 to 2026.
Antihypertensive drugs are employed for the treatment of patients suffering from hypertension. Hypertension is a medical condition, which involves rise in blood pressure in the arteries. Furthermore, the patient suffering from hypertension is highly susceptible to other complications, which include heart failure and aneurysm. Therefore, the treatment of this medical condition requires early diagnosis and management by the use of antihypertensive drugs. Some of the antihypertensive drugs available in the market include beta blockers, calcium channel blockers, and vasodilators. These drugs are prescribed by a physician, and are available in retail stores and hospital pharmacies.
The growth of the global antihypertensive market is driven by surge in incidence of hypertension across the globe. Furthermore, rise in awareness related to complications associated with hypertension is another major factor that fuels the growth of the market. Moreover, increase in geriatric population and sedentary lifestyle act as key drivers of the global market. However, recent patent expirations hinder the growth of the antihypertensive market. Conversely, surge in research related to antihypertensive drugs in emerging economies is expected to offer lucrative opportunities during the forecast period.
The global antihypertensive market size is segmented into therapeutic class, distribution channel, and region. On the basis of therapeutic class, the market is fragmented into diuretics, ACE inhibitors, calcium channel blockers, vasodilators, beta-adrenergic blockers, and others. Depending on distribution channel, it is segregated into retail pharmacy, hospital pharmacy, and e-commerce. Region wise, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
This report entails a detailed quantitative analysis along with the current global antihypertensive market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
The market size and estimations are based on a comprehensive analysis of key developments in the industry.
A qualitative analysis based on innovative products facilitates strategic business planning.
The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments
By Therapeutic Class
o Diuretics
o ACE Inhibitors
o Calcium Channel Blockers
o Beta-adrenergic Blockers
o Vasodilators
o Others
By Distribution Channel
o Retail Pharmacy
o Hospital Pharmacy
o E-commerce
By Region
o North America
U.S.
Canada
Mexico
o Europe
Germany
France
UK
Italy
Spain
Rest of Europe
o Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
o LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
List of key players profiled in the report
Boehringer Ingelheim GmbH
Merck KGaA
Johnson and Johnson
Bayer AG
Pfizer, Inc.
Takeda Pharmaceutical Co., Ltd.
AstraZeneca plc
Daiichi Sankyo Company
Sanofi S.A.
Novartis International AG
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
Merck
United Therapeutics Corporation Safe In Breastfeeding
 
READ MORE

Scope

Chapter 1: Introduction

 

1.1. Report Description

1.2. Key Market Segments

 

1.2.1. List of Key Players Profiled In The Report

 

1.3. Research Methodology

 

1.3.1. Primary Research

1.3.2. Secondary Research

1.3.3. Analyst Tools And Models

 

Chapter 2: Executive Summary

 

2.1. Key Findings of The Study

2.2. Cxo Perspective

 

Chapter 3: Market Overview

 

3.1. Market Definition And Scope

3.2. Top Player Positioning

 

3.2.1. Top Investment Pockets

 

3.3. Key Forces Shaping Antihypertensive Industry/Market

3.4. Market Dynamics

 

3.4.1. Drivers

 

3.4.1.1. Surge In Geriatric Population Worldwide

3.4.1.2. Surge In Healthcare Expenditure Worldwide

3.4.1.3. Rise In Prevalence of Hypertension Across The Globe

 

3.4.2. Restraint

 

3.4.2.1. Patent Expirations of Blockbuster Drugs

 

3.4.3. Opportunity

 

3.4.3.1. High Growth Potential In Developing Economies

 

3.4.4. Impact Analyses

 

Chapter 4: Antihypertensive Drugs Market, By Drug Class

 

4.1. Overview

 

4.1.1. Market Size And Forecast

 

4.2. Diuretics

 

4.2.1. Key Market Trends, Growth Factors, And Opportunities

4.2.2. Market Size And Forecast, By Region

4.2.3. Market Analysis By Country

 

4.3. Ace Inhibitors

 

4.3.1. Key Market Trends, Growth Factors, And Opportunities

4.3.2. Market Size And Forecast, By Region

4.3.3. Market Analysis By Country

 

4.4. Calcium Channel Blockers

 

4.4.1. Key Market Trends, Growth Factors, And Opportunities

4.4.2. Market Size And Forecast, By Region

4.4.3. Market Analysis By Country

 

4.5. Beta-Adrenergic Blockers

 

4.5.1. Key Market Trends, Growth Factors, And Opportunities

4.5.2. Market Size And Forecast, By Region

4.5.3. Market Analysis By Country

 

4.6. Vasodilators

 

4.6.1. Key Market Trends, Growth Factors, And Opportunities

4.6.2. Market Size And Forecast, By Region

4.6.3. Market Analysis By Country

 

4.7. Others

 

4.7.1. Key Market Trends, Growth Factors, And Opportunities

4.7.2. Market Size And Forecast, By Region

4.7.3. Market Analysis By Country

 

Chapter 5: Antihypertensive Drugs Market, By End User

 

5.1. Overview

 

5.1.1. Market Size And Forecast

 

5.2. Retail Pharmacy

 

5.2.1. Market Size And Forecast, By Region

5.2.2. Market Analysis By Country

 

5.3. Hospital Pharmacy

 

5.3.1. Market Size And Forecast, By Region

5.3.2. Market Analysis By Country

 

5.4. E-Commerce Websites & Online Drug Stores

 

5.4.1. Market Size And Forecast, By Region

5.4.2. Market Analysis By Country

 

Chapter 6: Antihypertensive Drugs Market, By Region

 

6.1. Overview

 

6.1.1. Market Size And Forecast

 

6.2. North America

 

6.2.1. Key Market Trends And Opportunities

6.2.2. Market Analysis, By Country

 

6.2.2.1. U.S.

 

6.2.2.1.1. U.S. Market Size And Forecast, By Drug Class

6.2.2.1.2. U.S. Market Size And Forecast, By Distribution Channel

 

6.2.2.2. Canada

 

6.2.2.2.1. Canada Market Size And Forecast, By Drug Class

6.2.2.2.2. Canada Market Size And Forecast, By Distribution Channel

 

6.2.2.3. Mexico

 

6.2.2.3.1. Mexico Market Size And Forecast, By Drug Class

6.2.2.3.2. Mexico Market Size And Forecast, By Distribution Channel

 

6.2.3. North America Market Size And Forecast, By Drug Class

6.2.4. North America Market Size And Forecast, By Distribution Channel

 

6.3. Europe

 

6.3.1. Key Market Trends And Opportunities

6.3.2. Market Analysis, By Country

 

6.3.2.1. Germany

 

6.3.2.1.1. Germany Market Size And Forecast, By Drug Class

6.3.2.1.2. Germany Market Size And Forecast, By Distribution Channel

 

6.3.2.2. France

 

6.3.2.2.1. France Market Size And Forecast, By Drug Class

6.3.2.2.2. France Market Size And Forecast, By Distribution Channel

 

6.3.2.3. Uk

 

6.3.2.3.1. Uk Market Size And Forecast, By Drug Class

6.3.2.3.2. Uk Market Size And Forecast, By Distribution Channel

 

6.3.2.4. Italy

 

6.3.2.4.1. Italy Market Size And Forecast, By Drug Class

6.3.2.4.2. Italy Market Size And Forecast, By Distribution Channel

 

6.3.2.5. Rest of Europe

 

6.3.2.5.1. Rest of Europe Market Size And Forecast, By Drug Class

6.3.2.5.2. Rest of Europe Market Size And Forecast, By Distribution Channel

 

6.3.3. Europe Market Size And Forecast, By Drug Class

6.3.4. Europe Market Size And Forecast, By Distribution Channel

 

6.4. Asia-Pacific

 

6.4.1. Key Market Trends And Opportunities

6.4.2. Market Analysis, By Country

 

6.4.2.1. Japan

 

6.4.2.1.1. Japan Market Size And Forecast, By Drug Class

6.4.2.1.2. Japan Market Size And Forecast, By Distribution Channel

 

6.4.2.2. China

 

6.4.2.2.1. China Market Size And Forecast, By Drug Class

6.4.2.2.2. China Market Size And Forecast, By Distribution Channel

 

6.4.2.3. India

 

6.4.2.3.1. India Market Size And Forecast, By Drug Class

6.4.2.3.2. India Market Size And Forecast, By Distribution Channel

 

6.4.2.4. Rest of Asia-Pacific

 

6.4.2.4.1. Rest of Asia-Pacific Market Size And Forecast, By Drug Class

6.4.2.4.2. Rest of Asia-Pacific Market Size And Forecast, By Distribution Channel

 

6.4.3. Asia-Pacific Market Size And Forecast, By Drug Class

6.4.4. Asia-Pacific Market Size And Forecast, By Distribution Channel

 

6.5. Lamea

 

6.5.1. Key Market Trends And Opportunities

6.5.2. Market Analysis, By Country

 

6.5.2.1. Brazil

 

6.5.2.1.1. Brazil Market Size And Forecast, By Drug Class

6.5.2.1.2. Brazil Market Size And Forecast, By Distribution Channel

 

6.5.2.2. South Africa

 

6.5.2.2.1. South Africa Market Size And Forecast, By Drug Class

6.5.2.2.2. South Africa Market Size And Forecast, By Distribution Channel

 

6.5.2.3. Saudi Arabia

 

6.5.2.3.1. Saudi Arabia Market Size And Forecast, By Drug Class

6.5.2.3.2. Saudi Arabia Market Size And Forecast, By Distribution Channel

 

6.5.2.4. Rest of Lamea

 

6.5.2.4.1. Rest of Lamea Market Size And Forecast, By Drug Class

6.5.2.4.2. Rest of Lamea Market Size And Forecast, By Distribution Channel

 

6.5.3. Lamea Market Size And Forecast, By Drug Class

6.5.4. Lamea Market Size And Forecast, By Distribution Channel

 

Chapter 7: Company Profiles

 

7.1. Astrazeneca Plc

 

7.1.1. Company Overview

7.1.2. Company Snapshot

7.1.3. Operating Business Segments

7.1.4. Product Portfolio

7.1.5. Business Performance

 

7.2. Boehringer Ingelheim International Gmbh

 

7.2.1. Company Overview

7.2.2. Company Snapshot

7.2.3. Operating Business Segments

7.2.4. Product Portfolio

7.2.5. Business Performance

 

7.3. Daiichi Sankyo Company, Limited

 

7.3.1. Company Overview

7.3.2. Operating Business Segments

7.3.3. Product Portfolio

7.3.4. Business Performance

7.3.5. Key Strategic Moves And Developments

 

7.4. Johnson & Johnson

 

7.4.1. Company Overview

7.4.2. Company Snapshot

7.4.3. Operating Business Segments

7.4.4. Product Portfolio

7.4.5. Business Performance

 

7.5. Lupin

 

7.5.1. Company Overview

7.5.2. Company Snapshot

7.5.3. Operating Business Segments

7.5.4. Product Portfolio

7.5.5. Business Performance

 

7.6. Novartis Ag.

 

7.6.1. Company Overview

7.6.2. Company Snapshot

7.6.3. Operating Business Segments

7.6.4. Product Portfolio

7.6.5. Business Performance

 

7.7. Merck & Co., Inc

 

7.7.1. Company Overview

7.7.2. Company Snapshot

7.7.3. Operating Business Segments

7.7.4. Product Portfolio

7.7.5. Business Performance

 

7.8. Pfizer Inc.

 

7.8.1. Company Overview

7.8.2. Company Snapshot

7.8.3. Operating Business Segments

7.8.4. Product Portfolio

7.8.5. Business Performance

 

7.9. Sun Pharmaceutical Industries Ltd. (Ranbaxy Laboratories)

 

7.9.1. Company Overview

7.9.2. Company Snapshot

7.9.3. Operating Business Segments

7.9.4. Product Portfolio

7.9.5. Business Performance

7.9.6. Key Strategic Moves And Developments

 

7.10. Sanofi

 

7.10.1. Company Overview

7.10.2. Operating Business Segments

7.10.3. Product Portfolio

7.10.4. Business Performance


List Of Figure

List of Figures

 

Figure 01. Global Antihypertensive Drugs Market Segmentation

Figure 02. Top Player Positioning, 2018

Figure 03. Top Investment Pockets

Figure 04. Moderate Bargaining Power of Supplier

Figure 05. Low Bargaining Power of Buyers

Figure 06. Low Threat of Substitutes

Figure 07. High Intensity of Rivalry

Figure 08. Low Threat of New Entrant

Figure 09. World Population Aged 65 And Over (%)

Figure 10. Impact Analyses, Antihypertensive Drugs Market

Figure 11. Comparative Share Analysis of Diuretics Market, By Country, 2018 & 2026 (%)

Figure 12. Comparative Share Analysis of Ace Inhibitors Antihypertensive Drugs Market, By Country, 2018 & 2026 (%)

Figure 13. Comparative Share Analysis of Calcium Channel Blockers Antihypertensive Drugs Market, By Country, 2018 & 2026 (%)

Figure 14. Comparative Share Analysis of Beta-Adrenergic Blockers Antihypertensive Drugs Market, By Country, 2018 & 2026 (%)

Figure 15. Comparative Share Analysis of Vasodilators Antihypertensive Drugs Market, By Country, 2018 & 2026 (%)

Figure 16. Comparative Share Analysis of Others Antihypertensive Drugs Market, By Country, 2018 & 2026 (%)

Figure 17. Comparative Share Analysis of Antihypertensive Drugs Market For Retail Pharmacy, By Country, 2018 & 2026 (%)

Figure 18. Comparative Share Analysis of Antihypertensive Drugs Market For Hospital Pharmacy, By Country, 2018 & 2026 (%)

Figure 19. Comparative Share Analysis of Antihypertensive Drugs Market For E-Commerce Websites & Online Drug Stores, By Country, 2018 & 2026 (%)

Figure 20. U.S. Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 21. Canada Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 22. Mexico Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 23. Comparison of Male Geriatric Population In European Countries, 2017 (Million)

Figure 24. Germany Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 25. France Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 26. Uk Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 27. Italy Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 28. Rest of Europe Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 29. Japan Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 30. China Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 31. India Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 32. Rest of Asia-Pacific Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 33. Brazil Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 34. South Africa Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 35. Saudi Arabia Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 36. Rest of Lamea Antihypertensive Drugs Market, 2018-2026 (USD Million)

Figure 37. Astrazeneca: Net Sales, 2016-2018 (USD Million)

Figure 38. Astrazeneca: Revenue Share By Region, 2018(%)

Figure 39. Boehringer Ingelheim: Net Sales, 2016-2018 (USD Million)

Figure 40. Boehringer Ingelheim: Revenue Share By Segment, 2018 (%)

Figure 41. Boehringer Ingelheim: Revenue Share By Region, 2018(%)

Figure 42. Daiichi-Sankyo: Net Sales, 2016-2018 (USD Million)

Figure 43. Daiichi-Sankyo: Revenue Share By Segment, 2018 (%)

Figure 44. Daiichi-Sankyo: Revenue Share By Region, 2018(%)

Figure 45. J&J: Net Sales, 2016-2018 (USD Million)

Figure 46. J&J: Revenue Share By Segment, 2018 (%)

Figure 47. J&J: Revenue Share By Region, 2018(%)

Figure 48. Lupin: Net Sales, 2017-2019 (USD Million)

Figure 49. Lupin: Revenue Share By Region, 2019(%)

Figure 50. Novartis Ag: Net Sales, 2016-2018 (USD Million)

Figure 51. Novartis Ag: Revenue Share By Segment, 2018 (%)

Figure 52. Novartis Ag: Revenue Share By Geography, 2018 (%)

Figure 53. Merck: Net Sales, 2016-2018 (USD Million)

Figure 54. Merck: Revenue Share By Segment, 2018 (%)

Figure 55. Merck: Revenue Share By Region, 2018(%)

Figure 56. Pfizer: Net Sales, 2016-2018 (USD Million)

Figure 57. Pfizer: Revenue Share By Segment, 2018 (%)

Figure 58. Pfizer: Revenue Share By Region, 2018(%)

Figure 59. Sun Pharma: Net Sales, 2016-2018 (USD Million)

Figure 60. Sun Pharma: Revenue Share By Region, 2018(%)

Figure 61. Sanofi: Net Sales, 2016-2018 (USD Million)

Figure 62. Sanofi: Revenue Share By Segment, 2018 (%)

Figure 63. Sanofi: Revenue Share By Region, 2018(%)


List Of Table

List of Tables

 

Table 01. Global Antihypertensive Drugs Market, By Drug Class, 2018-2026 (USD Million)

Table 02. Diuretics Antihypertensive Drugs Market, By Region, 2018-2026 (USD Million)

Table 03. Ace Inhibitors Antihypertensive Drugs Market, By Region, 2018-2026 (USD Million)

Table 04. Calcium Channel Blockers Antihypertensive Drugs Market, By Region, 2018-2026 (USD Million)

Table 05. Beta-Adrenergic Blockers Antihypertensive Drugs Market, By Region, 2018-2026 (USD Million)

Table 06. Vasodilators Antihypertensive Drugs Market, By Region, 2018-2026 (USD Million)

Table 07. Others Antihypertensive Drugs Market, By Region, 2018-2026 (USD Million)

Table 08. Global Antihypertensive Drugs Market, By Distribution Channel, 2018-2026 (USD Million )

Table 09. Antihypertensive Drugs Market Revenue For Retail Pharmacy, By Region 2018-2026(USD Million)

Table 10. Antihypertensive Drugs Market Revenue For Hospital Pharmacy, By Region 2018-2026 (USD Million)

Table 11. Antihypertensive Drugs Market Revenue For E-Commerce Websites & Online Drug Stores, By Region 2018-2026 (USD Million)

Table 12. Antihypertensive Drugs Market, By Region, 2018-2026 (USD Million)

Table 13. North America Antihypertensive Drugs Market Revenue, By Country, 2019-2026 (USD Million)

Table 14. U.S. Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 15. U.S. Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 16. Canada Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 17. Canada Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 18. Mexico Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 19. Mexico Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 20. North America Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026(USD Million)

Table 21. North America Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026(USD Million)

Table 22. Europe Antihypertensive Drugs Market Revenue, By Country, 2019-2026 (USD Million)

Table 23. Germany Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 24. Germany Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 25. France Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 26. France Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 27. Uk Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 28. Uk Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 29. Italy Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 30. Italy Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 31. Rest of Europe Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 32. Rest of Europe Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 33. Europe Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026(USD Million)

Table 34. Europe Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026(USD Million)

Table 35. Asia-Pacific Antihypertensive Drugs Market Revenue, By Country, 2019-2026 (USD Million)

Table 36. Japan Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 37. Japan Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 38. China Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 39. China Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 40. India Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 41. India Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 42. Rest of Asia-Pacific Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 43. Rest of Asia-Pacific Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 44. Asia-Pacific Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026(USD Million)

Table 45. Asia-Pacific Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026(USD Million)

Table 46. Lamea Antihypertensive Drugs Market Revenue, By Country, 2019-2026 (USD Million)

Table 47. Brazil Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 48. Brazil Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 49. South Africa Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 50. South Africa Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 51. Saudi Arabia Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 52. Saudi Arabia Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 53. Rest of Lamea Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 54. Rest of Lamea Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026 (USD Million)

Table 55. Lamea Antihypertensive Drugs Market Revenue, By Drug Class, 2019-2026(USD Million)

Table 56. Lamea Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019-2026(USD Million)

Table 57. Astrazeneca: Company Snapshot

Table 58. Astrazeneca: Operating Business Segments

Table 59. Astrazeneca: Product Portfolio

Table 60. Boehringer Ingelheim: Company Snapshot

Table 61. Boehringer Ingelheim: Product Business Segments

Table 62. Boehringer Ingelheim: Product Portfolio

Table 63. Daiichi-Sankyo.: Company Snapshot

Table 64. Daiichi-Sankyo.: Operating Business Segments

Table 65. Daiichi-Sankyo.: Product Portfolio

Table 66. J&J: Company Snapshot

Table 67. J&J: Operating Business Segments

Table 68. J&J: Product Portfolio

Table 69. Lupin: Company Snapshot

Table 70. Lupin: Operating Segments

Table 71. Lupin: Product Portfolio

Table 72. Novartis: Company Snapshot

Table 73. Novartis: Operating Business Segments

Table 74. Novartis: Product Portfolio

Table 75. Merck: Company Snapshot

Table 76. Merck: Operating Segments

Table 77. Merck: Product Portfolio

Table 78. Pfizer: Company Snapshot

Table 79. Pfizer: Operating Segments

Table 80. Pfizer: Product Portfolio

Table 81. Sun Pharma: Company Snapshot

Table 82. Sun Pharma: Product Portfolio

Table 83. Sanofi: Company Snapshot

Table 84. Sanofi: Product Portfolio

Single-User license:

This  grants one non-exclusive, non-transferable machine-readable license for the report either electronically or online. The right to store, display, use, or stockpile the report is restricted to only ONE authorized computer. For obtaining a single user license, ONLY an individual ("you") for individual use is entitled for using the product or as mentioned in the License Terms. Any individual representing an organization is refrained from accessing the products/services of AMR or as stated in the License Terms; any breach of which shall lead to violation of applicable laws in the United States, India, or in the jurisdiction of purchase. The products and services offered are the intellectual property of AMR, and are protected by applicable copyright laws, international treaty provisions, and other applicable laws of the country in which these are being used. Albeit the abovementioned, you are NOT be permitted to:

transmit or permit any third party to use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to assign the rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial/noncommercial gains

share the information or content either electronically or in printed form with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization or any other unauthorized users.

 

Five-User License:

This  grants up to Five non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online. The right to store, transfer, display, use, or stockpile the report is restricted to only FIVE authorized users. An individual representing an organization or an organization shall ONLY purchase the five-user license. The authorized users can print additional duplicate printed copies of the report for distribution to the employees of his/her company (Personnel). Albeit the abovementioned, you are NOT be permitted to:

 

transmit or permit by any means to any third party (i.e. non-personnel) or unauthorized users for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to redistribute or assign rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; exclusively permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial or noncommercial gains.

share the information or content either electronically or as printed copies with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization, or to more than 5 AUTHORIZED USERS.

 

Enterprise License:

This  grants global, non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online, within the organization and/or its subsidiaries. The authorized users shall have complete right to store, display, transfer, and/or use the report ONLY within the organization or its subsidiaries. Authorized users can take unlimited printed copies of the report for distribution among its employees. Albeit the abovementioned, you shall NOT be permitted to:

transmit or permit by any means to any third party (i.e. non-personnel) for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer or attempt to assign the rights in the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Boehringer Ingelheim GmbH, Merck KGaA, Johnson and Johnson, Bayer AG, Pfizer, Inc. Takeda Pharmaceutical Co., Ltd., AstraZeneca plc, Daiichi Sankyo Company, Sanofi S.A., and Novartis International AG.